Ribociclib (Kisqali) in combination with fulvestrant has been PBS-listed for the treatment of patients with HR-positive, HER2-negative unresectable advanced or metastatic breast cancer. Pivotal studies included the MONALEESA-3 trial which showed overall survival with the CDK4/6 inhibitor plus fulvestrant was significantly longer than with fulvestrant alone in this group of patients (OS at 42 months ...
New options for advanced breast cancer listed on PBS
By Mardi Chapman
30 Mar 2021